DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
Current Location:
> This Story

Log in or Register to rate this News Story
Forward Printable StoryPrint Comment



Alzheimers/Neurology Homepage

Study suggests most emergency CT exams for head trauma may be unnecessary Not in line with current medical criteria

Functional MR with machine learning may predict patient response to OCD treatment Technique could yield major cost savings

Seizure-monitoring smart watch scores FDA clearance Empatica's Embrace detects life-threatening grand mal seizures

Study shows the limitations of machine learning in neuroscience research Functional MR imaging on its own is more accurate

Masimo's Next Generation SedLine brain function monitor scores FDA clearance Expected to be as revolutionary as rainbow SET

Eli Lilly's solanezumab fails to slow cognitive decline in Alzheimer's Drug targeting soluble amyloid falls short in a large clinical trial

Allegheny Health Network first in Penn. to use Synaptive's robotic surgery system Specifically for cranial and spinal procedures

Health Canada approves GE's DaTscan SPECT agent Can help distinguish Parkinson's disease from essential tremor

UK researchers 3-D print biological structures for tissue regeneration and replica organs A step closer to printing transplant organs

Hanalytics launches first AI center for neurology with Beijing hospital Will develop AI applications for brain tumors, vascular diseases and patient rehabilitation

Helen Jenkins

Alkahest appoints new chief operating officer
August 07, 2017
SAN CARLOS, Calif., Aug. 7, 2017 /PRNewswire/ -- Alkahest, Inc. ("Alkahest"), a clinical-stage biotechnology company focused on developing new treatments for neurodegenerative diseases and other age-related conditions, announced today that Helen Jenkins has joined the company's executive team as Chief Operating Officer. In this role, Ms. Jenkins will be responsible for translating corporate business priorities into operational tactics that achieve Alkahest's financial and strategic goals.

Ms. Jenkins joins Alkahest from Tobira Therapeutics, Inc. where she served as Chief Operating Officer, and played a key role in Tobira's acquisition by Allergan plc in a deal valued at up to $1.7 billion in November of 2016.

Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED

"Helen is an outstanding drug developer with an excellent track record of industry leadership," said Dr. Karoly Nikolich, Co-Founder, Chairman and CEO of Alkahest. "Helen brings extensive product development and management expertise to Alkahest and shares our dedication to discover and develop effective therapies for neurodegenerative diseases."

"I am thrilled to join Alkahest's leadership team, and to participate in the progression of the Company's preclinical and clinical stage pipeline. We are entering into an unprecedented period of productivity in the development of therapies for age-related diseases, and it's exciting to be at the forefront," said Ms. Jenkins.

Ms. Jenkins brings nearly 30 years of drug development experience in biotechnology to Alkahest, highlighted by a strong understanding of science, drug development, project management and regulatory requirements. Before serving in multiple roles of increasing responsibility at Tobira, Helen served as a corporate officer at Nuon Therapeutics, Inc. and Saegis Pharmaceuticals, where she was responsible for development operations, strategic planning and portfolio management. Prior to Nuon and Saegis, Ms. Jenkins was Senior Director, Product Development/Regulatory Affairs, at Valentis, Inc., and she previously led preclinical programs through successful IND filings during her tenures at Glycomed Inc. and Genentech, Inc. Ms. Jenkins has a Masters of Arts in cellular and molecular biology from San Francisco State University, San Francisco, CA.

About Alkahest
Alkahest is developing treatments for age-related diseases, with an emphasis on cognitive dysfunction and dementia -- key medical challenges of our generation. The company's breakthrough research has demonstrated that factors in blood plasma of young animals are able to reverse brain deficits in normal aging and Alzheimer's disease models in animals. Alkahest is a clinical-stage private company based in San Carlos, CA, with investors including Barcelona, Spain-based Grifols, a global healthcare company and leading producer of plasma therapies, as well as a collaboration and commercialization partner. For further information, see

SOURCE Alkahest, Inc.

Alzheimers/Neurology Homepage

You Must Be Logged In To Post A Comment

Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Gold Service Dealer Program
Receive RFP/PS
Healthcare Providers
See all
HCP Tools
A Job
Parts Hunter +EasyPay
Get Parts
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to, Inc. Copyright ©2001-2018, Inc.